Malignant pleural mesothelioma is a cancer mainly caused by asbestos exposure that is very deadly. Research continues to be done on the cancer, giving hope to patients and their families. One tool in the fight against mesothelioma is ex-vivo models using precision cut tumor slices. A new article looks at[…]
Pleural Mesothelioma
Pleurectomy and Decortication Vs Just Chemotherapy for Mesothelioma
Malignant pleural mesothelioma is a rare and deadly cancer mainly caused by asbestos exposure. It is hard to surgically remove and is very aggressive, which makes it hard to treat. A trial known as the MARS 2 trial investigated to see if pleurectomy and decortication could improve the quality of[…]
Surgery is Beneficial for Mesothelioma Patients
Pleural mesothelioma is a cancer mainly caused by asbestos exposure. It is a cancer of the pleura, which is a lining of the lungs. The outlook for the disease is poor, with a typical survival time after diagnosis being 9 to 20 months. The overall five-year survival rate is five[…]
Changes to Staging System for Mesothelioma
Malignant pleural mesothelioma is a rare cancer associated with asbestos exposure. Two very important aspects of treating mesothelioma are classification and staging. They are important because they guide treatment and predict outcomes. One system to classify cancers is the TNM system which was created by the IASLC. It classifies cancers[…]
Pleural Therapies Can Help Pleural Mesothelioma Patients
Malignant mesothelioma is a cancer of the mesothelium, which is the lining of certain areas of the body including the lungs (called the pleura). It is mainly caused by asbestos, and usually occurs 30 to 50 years after initial asbestos exposure. Mesothelioma has a poor outlook, with most patients living[…]
Multimodal Therapy Helps Improve Survival in Mesothelioma Patients
Malignant pleural mesothelioma is an aggressive cancer mainly caused by asbestos exposure. It is a cancer of the mesothelium, which is the lining of certain areas of the body including the lungs. The cancer is aggressive and hard to treat. There is hope though in new surgical and therapy methods.[…]
Ga-68 FAPI PET Before Immunotherapy (FAPBI)
It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.
A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001)
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
Keytruda and Chemotherapy Improve Survival in Mesothelioma Patients
The U.S Food and Drug Administration has accepted a priority review for a new Supplemental Biologics License Application. This could be a new era in the management of pleural mesothelioma, leading to a better future for those diagnosed with the cancer. The review is looking for approval of Keytruda used[…]
ACADL Could Help with the Diagnosis of Mesothelioma
Mesothelioma, a cancer mainly caused by asbestos exposure, is typically found in older Americans. One problem with mesothelioma is that it is hard to tell between reactive and cancerous cells. A study in the American Journal of Pathology sheds light and expands on this information. The study found a biomarker,[…]